A mint-family herb with a long traditional record and a small modern evidence base. The most consistent findings are calmer mood, better self-rated sleep, modestly lower blood fats and modestly lower upper blood pressure. The calming effect and the drawback are the same thing: alertness measurably drops at doses that help. Nothing here is settled in either direction. (Full Review)

Protocol

Standard oral protocol

300–600 mg standardised leaf extract

Once or twice daily, or 600 mg once daily as a single evening dose, taken with food to increase polyphenol exposure.

Best time of day

Evening

Standard because sedation is the dominant acute effect. Split daytime dosing is used only when the target is anxiety rather than sleep, and then at the low end.

European regulatory dosing

1.5–4.5 g herb infused

In 150 mL water one to three times daily, or 2–6 mL of a 1:5 tincture at the same frequency.

Time to effect

Calming and sleep effects

1–3 hours

Within one to three hours of a single dose.

Lipid, blood pressure and glucose changes

8–12 weeks

Of daily use in the trials that found them.

Reduced palpitation episodes

14 days

Of freeze-dried aqueous leaf extract in the single trial that measured it.

Benefits

Medium: Reduced anxiety and depressive symptoms; improved sleep quality; lower blood lipids; reduced systolic blood pressure

Low: Better glycemic control and lower inflammation in type 2 diabetes; relief of benign heart palpitations; acute cognitive performance after a single dose; reduced menstrual pain and premenstrual symptoms; faster resolution of recurrent cold sores; improved arterial stiffness and skin elasticity; reduced agitation in dementia

Speculative: Slowed cognitive decline; broader antiviral activity; anti-inflammatory and antioxidant signalling relevant to aging; relief of mild digestive cramping and bloating

Contraindications

Pregnancy and lactation

Diagnosed or subclinical hypothyroidism with thyrotropin above 4.0 mIU/L, or Hashimoto's thyroiditis

Children under 12 years

Scheduled surgery within two weeks

Untreated moderate-to-severe obstructive sleep apnoea (more than 15 events per hour)

Occupations requiring sustained vigilance within six hours of dosing

Key Interactions

Prescription sedatives and hypnotics (diazepam, zolpidem, phenobarbital)

Sedating antihistamines (diphenhydramine, chlorphenamine, promethazine)

Thyroid hormone replacement (levothyroxine, liothyronine)

Blood-pressure medicines (lisinopril, losartan, amlodipine)

Glucose-lowering agents (metformin, glipizide, insulin)

Anticholinergic drugs (oxybutynin, amitriptyline)

Alcohol

Sedating supplements (valerian, kava, passionflower, melatonin, GABA, glycine, high-dose magnesium)

Blood-pressure-lowering supplements (beetroot nitrate, hibiscus, garlic extract, high-dose omega-3)

Topical antiviral therapy (aciclovir cream, docosanol)

Non-drug interventions (evening sauna, alcohol-free wind-down protocols, magnesium baths)

Risk & Side Effects

Medium: Dose-dependent sedation and reduced alertness

Low: Mild gastrointestinal symptoms; headache; additive sedation with central nervous system depressants; interference with thyroid hormone signalling; withdrawal-type symptoms after abrupt discontinuation

Speculative: Additive blood-pressure lowering; unknown risk in pregnancy and lactation; toxicity of orally ingested essential oil; allergic contact dermatitis from topical use

Monitoring

Marker	Target	Why
Thyrotropin (TSH)	0.5–2.0 mIU/L	The signal lemon balm may theoretically blunt
Free thyroxine (free T4)	1.0–1.5 ng/dL	Confirms gland output if thyrotropin drifts
Total cholesterol	160–200 mg/dL	The lipid marker that moved in both meta-analyses
Triglycerides	60–90 mg/dL	The most responsive lipid in the pooled trials
LDL cholesterol	70–100 mg/dL	Fell modestly in the lipid meta-analysis
Fasting glucose	75–90 mg/dL	Screens the theoretical additive hypoglycemia risk
Glycated hemoglobin (HbA1c)	4.8–5.4%	Confirms whether a glucose shift is sustained
High-sensitivity C-reactive protein (hs-CRP)	<1.0 mg/L	The inflammation marker that fell in the diabetes trial
Systolic blood pressure (home)	110–120 mmHg	The best-replicated cardiovascular effect
Alanine aminotransferase (ALT)	10–26 U/L (men), 10–19 U/L (women)	Liver safety marker for continuous polyphenol exposure
Serum rosmarinic acid	No established target exists	Would confirm absorption from a given product

Cadence: Baseline panel before starting. Lipids, glucose and inflammation markers repeated at 12 weeks, then every 6 to 12 months. Thyrotropin rechecked at 12 weeks and annually thereafter, or within 6 weeks of any dose increase. Home blood pressure logged weekly for the first month, then monthly.

Qualitative Assessment

Sleep onset latency and number of night awakenings, logged nightly for two weeks before and after starting
Insomnia Severity Index score, rescored at 4 and 12 weeks
Morning grogginess on waking, which distinguishes a useful dose from an excessive one
Daytime alertness and reaction speed, self-rated at mid-morning
Subjective calm under a known stressor, rated on the same recurring situation rather than in general
Frequency and intensity of palpitation episodes, where that is the reason for use

Lemon Balm for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment